[HTML][HTML] The association between the neuroendocrine system and the tumor immune microenvironment: emerging directions for cancer immunotherapy
J Li, M Che, B Zhang, K Zhao, C Wan, K Yang - Biochimica et Biophysica …, 2023 - Elsevier
This review summarizes emerging evidence that the neuroendocrine system is involved in
the regulation of the tumor immune microenvironment (TIME) to influence cancer …
the regulation of the tumor immune microenvironment (TIME) to influence cancer …
Exploring the constitutive activation mechanism of the class A orphan GPR20
M Zhang, J Ao, N Liu, T Chen, S Lu - Acta Pharmacologica Sinica, 2024 - nature.com
GPR20, an orphan G protein-coupled receptor (GPCR), shows significant expression in
intestinal tissue and represents a potential therapeutic target to treat gastrointestinal stromal …
intestinal tissue and represents a potential therapeutic target to treat gastrointestinal stromal …
Distinct binding conformations of epinephrine with α-and β-adrenergic receptors
Agonists targeting α2-adrenergic receptors (ARs) are used to treat diverse conditions,
including hypertension, attention-deficit/hyperactivity disorder, pain, panic disorders, opioid …
including hypertension, attention-deficit/hyperactivity disorder, pain, panic disorders, opioid …
Blocking α1 Adrenergic Receptor as a Novel Target for Treating Alzheimer's Disease
X Pan, Z Lei, J Chen, C Jia, J Deng, Y Liu… - ACS Chemical …, 2024 - ACS Publications
While amyloidopathy and tauopathy have been recognized as hallmarks in Alzheimer's
disease (AD) brain, recently, increasing lines of evidence have supported the pathological …
disease (AD) brain, recently, increasing lines of evidence have supported the pathological …
Structural basis of tolvaptan binding to the vasopressin V2 receptor
H Liu, H Zhong, Y Zhang, H Xue, Z Zhang… - Acta Pharmacologica …, 2024 - nature.com
The vasopressin V2 receptor (V2R) is a validated therapeutic target for autosomal dominant
polycystic kidney disease (ADPKD), with tolvaptan being the first FDA-approved antagonist …
polycystic kidney disease (ADPKD), with tolvaptan being the first FDA-approved antagonist …
Ligand–Receptor Interactions and Structure–Function Relationships in Off-Target Binding of the β3-Adrenergic Agonist Mirabegron to α1A-Adrenergic Receptors
The β3-adrenoceptor agonist mirabegron is available for the treatment of storage symptoms
of overactive bladder, including frequency, urgency, and incontinence. The off-target effects …
of overactive bladder, including frequency, urgency, and incontinence. The off-target effects …
Signalling of Adrenoceptors: Canonical Pathways and New Paradigms
The concept of G protein-coupled receptors initially arose from studies of the β-
adrenoceptor, adenylyl cyclase, and cAMP signalling pathway. Since then both canonical G …
adrenoceptor, adenylyl cyclase, and cAMP signalling pathway. Since then both canonical G …